Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Human immunodeficiency virus enfuvirtide

Deeks SG, Lu J, Hoh R, Neilands TB, Beatty G, Huang W, Liegler T, Hunt P, Martin JN, Kuritzkes DR (2007) Interruption of enfuvirtide in HIV-1 infected adults with incomplete viral suppression on an enfuvirtide-based regimen. J Infect Dis 195 387-391 Dejucq N, Simmons G, Clapham PR (2000) T-ceU line adaptation of human immunodeficiency virus type 1 strain SF162 effects on envelope, vpu and macrophage-tropism. J Gen Virol 81 2899-2904... [Pg.194]

Labrosse B, Morand-Joubert L, Goubard A, Rochas S, Labemardiere JL, Pacanowski J, Meynard JL, Hance AJ, Clavel E, Mammano E (2006) Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients. J Virol 80 8807-8819... [Pg.197]

Lu J, Sista P, Giguel F, Greenberg M, Kuritzkes DR (2004) Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20), J Virol 78 4628 637 Lu M, Blacklow SC, Kim PS (1995) A tiimeric structural domain of the HlV-1 transmembrane glycoprotein, Nat Struct Biol 2 1075-1082... [Pg.198]

Mink M, Mosier SM, Janumpalli S, Davison D, Jin L, Melby T, Sista P, Erickson J, Lambert D, Stanfleld-Oakley SA, Salgo M, Cammack N, Matthews T, Greenberg ML (2005) Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol 79 12447-12454... [Pg.318]

Enfuvirtide (Fuzeon , T-20, Ro 29-9800, Hoffmann-La Roche) is a 36-amino acid synthetic peptide with a molecular weight of 4492 Da. It selectively inhibits human immunodeficiency virus (HIV) fusion to the host cell membranes [73]. The N-terminus of the molecule is acetylated and the C-terminus is amidated. A metabolite, M-20, is deamidated at the C-terminus. An ELISA method was initially used during drug development of this compound, but the decision was made to develop and validate an LC-ESI-MS/MS method for the simultaneous determination of enfuvirtide and M-20 for PK studies to support the NDA submission of this product [53]. Some of the issues of LC-ESI-MS/MS application for peptide bioanalysis are highlighted in the following. [Pg.171]

X. Zhang, K. Nieforth, J. M. Lang, R. Rouzier-Panis, J. Reynes, A. Dorr, S. Kolis, M. R. Stiles, T. Kinchelow, and I. H. Patel, Pharmacokinetics of plasma enfuvirtide after subcutaneous administration to patients with human immunodeficiency virus inverse Gaussian density absorption and 2-compartment disposition. Clin Pharmacol Ther 72 10-19 (2002). [Pg.366]

Pan C, Cai L, Lu H et al (2009) Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide-sensitive and -resistant HIV type 1 strains. J Virol 83 7862-7872... [Pg.160]

Naito T, Izumi K, Kodama E et al (2009) SC29EK, a peptide fusion inhibitor with enhanced a -helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother 53 1013-1018... [Pg.160]

J. S. Cervia and M. A. Smith, Enfuvirtide (T-20) a novel human immunodeficiency virus type 1 fusion inhibitor, Clin. Infect. Dis., 37 (2003) 1102-1106. [Pg.301]

See other pages where Human immunodeficiency virus enfuvirtide is mentioned: [Pg.194]    [Pg.195]    [Pg.199]    [Pg.199]    [Pg.199]    [Pg.200]    [Pg.201]    [Pg.528]    [Pg.325]    [Pg.196]    [Pg.196]    [Pg.189]   
See also in sourсe #XX -- [ Pg.193 ]



SEARCH



Enfuvirtide

Human immunodeficiency

Immunodeficiency

Immunodeficient

Viruses human

© 2024 chempedia.info